Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic

Jeffrey Stroup, Shannon M. Rivers, Asim M. Abu-Baker, Michael P. Kane

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Study Objectives. To determine changes in bone mineral density (BMD) and T scores of patients after 2 years of teriparatide therapy, and to determine the number of fractures that occurred during therapy Design. Prospective, observational study. Setting. Pharmacist-run teriparatide clinic in a private-practice endocrinology group. Patients. Sixty patients with osteoporosis who experienced fractures or adverse events while receiving antiresorptive therapy and were referred by the endocrinologists to the clinic between January 1, 2002, and January 1, 2004. Intervention. After a 1-hour counseling and training session with a clinical pharmacist, patients self-administered subcutaneous teriparatide 20 μg/day for the next 2 years. Measurements and Main Results. Primary outcome measures were dual x-ray absorptiometry-determined BMDs and T scores for the total hip, spine, and wrist at baseline and at 1 and 2 years. Patients' BMDs for the hip significantly increased by 3.5% at 1 year and by 3.9% at 2 years. In addition, BMD for the spine significantly increased by 7.2% at 1 year and 10.9% at 2 years. In 56 (93%) patients, BMD for the spine increased after 2 years of treatment. For the wrist, BMD decreased by 0.75% at 1 year and by 2.4% at 2 years, but the change was only significant at 2 years (p=0.011). At both 1 and 2 years, T scores for the total hip and spine significantly improved from baseline (p≤0.019), whereas T scores for the wrist significantly declined after 2 years of therapy (p<0.003). No new fractures were documented in any of the patients. Conclusion. In patients with osteoporosis, the use of teriparatide in a pharmacist-run clinic significantly increased BMD at the total hip and spinal sites and significantly decreased BMD in the wrist.

Original languageEnglish
Pages (from-to)779-788
Number of pages10
JournalPharmacotherapy
Volume27
Issue number6
DOIs
StatePublished - 1 Jun 2007

Fingerprint

Teriparatide
Pharmacists
Bone Density
Wrist
Hip
Spine
Osteoporosis
Therapeutics
Endocrinology
Private Practice
Observational Studies
Counseling
X-Rays
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • BMD
  • Bone mineral density
  • Osteoporosis
  • Pharmacist clinic
  • T score
  • Teriparatide

Cite this

Stroup, Jeffrey ; Rivers, Shannon M. ; Abu-Baker, Asim M. ; Kane, Michael P. / Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. In: Pharmacotherapy. 2007 ; Vol. 27, No. 6. pp. 779-788.
@article{6474cdfc457a4913b1544aa9ad0748a6,
title = "Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic",
abstract = "Study Objectives. To determine changes in bone mineral density (BMD) and T scores of patients after 2 years of teriparatide therapy, and to determine the number of fractures that occurred during therapy Design. Prospective, observational study. Setting. Pharmacist-run teriparatide clinic in a private-practice endocrinology group. Patients. Sixty patients with osteoporosis who experienced fractures or adverse events while receiving antiresorptive therapy and were referred by the endocrinologists to the clinic between January 1, 2002, and January 1, 2004. Intervention. After a 1-hour counseling and training session with a clinical pharmacist, patients self-administered subcutaneous teriparatide 20 μg/day for the next 2 years. Measurements and Main Results. Primary outcome measures were dual x-ray absorptiometry-determined BMDs and T scores for the total hip, spine, and wrist at baseline and at 1 and 2 years. Patients' BMDs for the hip significantly increased by 3.5{\%} at 1 year and by 3.9{\%} at 2 years. In addition, BMD for the spine significantly increased by 7.2{\%} at 1 year and 10.9{\%} at 2 years. In 56 (93{\%}) patients, BMD for the spine increased after 2 years of treatment. For the wrist, BMD decreased by 0.75{\%} at 1 year and by 2.4{\%} at 2 years, but the change was only significant at 2 years (p=0.011). At both 1 and 2 years, T scores for the total hip and spine significantly improved from baseline (p≤0.019), whereas T scores for the wrist significantly declined after 2 years of therapy (p<0.003). No new fractures were documented in any of the patients. Conclusion. In patients with osteoporosis, the use of teriparatide in a pharmacist-run clinic significantly increased BMD at the total hip and spinal sites and significantly decreased BMD in the wrist.",
keywords = "BMD, Bone mineral density, Osteoporosis, Pharmacist clinic, T score, Teriparatide",
author = "Jeffrey Stroup and Rivers, {Shannon M.} and Abu-Baker, {Asim M.} and Kane, {Michael P.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1592/phco.27.6.779",
language = "English",
volume = "27",
pages = "779--788",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Wiley-Blackwell",
number = "6",

}

Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. / Stroup, Jeffrey; Rivers, Shannon M.; Abu-Baker, Asim M.; Kane, Michael P.

In: Pharmacotherapy, Vol. 27, No. 6, 01.06.2007, p. 779-788.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic

AU - Stroup, Jeffrey

AU - Rivers, Shannon M.

AU - Abu-Baker, Asim M.

AU - Kane, Michael P.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Study Objectives. To determine changes in bone mineral density (BMD) and T scores of patients after 2 years of teriparatide therapy, and to determine the number of fractures that occurred during therapy Design. Prospective, observational study. Setting. Pharmacist-run teriparatide clinic in a private-practice endocrinology group. Patients. Sixty patients with osteoporosis who experienced fractures or adverse events while receiving antiresorptive therapy and were referred by the endocrinologists to the clinic between January 1, 2002, and January 1, 2004. Intervention. After a 1-hour counseling and training session with a clinical pharmacist, patients self-administered subcutaneous teriparatide 20 μg/day for the next 2 years. Measurements and Main Results. Primary outcome measures were dual x-ray absorptiometry-determined BMDs and T scores for the total hip, spine, and wrist at baseline and at 1 and 2 years. Patients' BMDs for the hip significantly increased by 3.5% at 1 year and by 3.9% at 2 years. In addition, BMD for the spine significantly increased by 7.2% at 1 year and 10.9% at 2 years. In 56 (93%) patients, BMD for the spine increased after 2 years of treatment. For the wrist, BMD decreased by 0.75% at 1 year and by 2.4% at 2 years, but the change was only significant at 2 years (p=0.011). At both 1 and 2 years, T scores for the total hip and spine significantly improved from baseline (p≤0.019), whereas T scores for the wrist significantly declined after 2 years of therapy (p<0.003). No new fractures were documented in any of the patients. Conclusion. In patients with osteoporosis, the use of teriparatide in a pharmacist-run clinic significantly increased BMD at the total hip and spinal sites and significantly decreased BMD in the wrist.

AB - Study Objectives. To determine changes in bone mineral density (BMD) and T scores of patients after 2 years of teriparatide therapy, and to determine the number of fractures that occurred during therapy Design. Prospective, observational study. Setting. Pharmacist-run teriparatide clinic in a private-practice endocrinology group. Patients. Sixty patients with osteoporosis who experienced fractures or adverse events while receiving antiresorptive therapy and were referred by the endocrinologists to the clinic between January 1, 2002, and January 1, 2004. Intervention. After a 1-hour counseling and training session with a clinical pharmacist, patients self-administered subcutaneous teriparatide 20 μg/day for the next 2 years. Measurements and Main Results. Primary outcome measures were dual x-ray absorptiometry-determined BMDs and T scores for the total hip, spine, and wrist at baseline and at 1 and 2 years. Patients' BMDs for the hip significantly increased by 3.5% at 1 year and by 3.9% at 2 years. In addition, BMD for the spine significantly increased by 7.2% at 1 year and 10.9% at 2 years. In 56 (93%) patients, BMD for the spine increased after 2 years of treatment. For the wrist, BMD decreased by 0.75% at 1 year and by 2.4% at 2 years, but the change was only significant at 2 years (p=0.011). At both 1 and 2 years, T scores for the total hip and spine significantly improved from baseline (p≤0.019), whereas T scores for the wrist significantly declined after 2 years of therapy (p<0.003). No new fractures were documented in any of the patients. Conclusion. In patients with osteoporosis, the use of teriparatide in a pharmacist-run clinic significantly increased BMD at the total hip and spinal sites and significantly decreased BMD in the wrist.

KW - BMD

KW - Bone mineral density

KW - Osteoporosis

KW - Pharmacist clinic

KW - T score

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=34249776074&partnerID=8YFLogxK

U2 - 10.1592/phco.27.6.779

DO - 10.1592/phco.27.6.779

M3 - Article

C2 - 17542760

AN - SCOPUS:34249776074

VL - 27

SP - 779

EP - 788

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -